Friday February 24th 2017: Novo Nordisk A/S, NVO is in the exchange NYSE and its industry is Drug Manufacturers – Other in the sector of Healthcare. Based in Denmark, Novo Nordisk A/S, NVO has a market cap of 84.45 B. Since its IPO date on the 01/04/1982, Novo Nordisk A/S, NVO performance year to date is 20.47%. Today Novo Nordisk A/S, NVO has gained 1.43%, with a current price of 43.2.
Ownership of the company is 26.40% for insider ownership while institutional ownership is 8.50%. The management of the company have seen the company have a payout ratio of 44.10%. Return of assets are at 42.10%, with return on investment at 84.70%.
In terms of debt levels and profit levels, Novo Nordisk A/S, NVO is seeing a long-term debt/equity of 0. While Total debt/equity is 0.02. With a profit margin of 34.20%, this is combined with a gross margin of 84.80%, and operating margin of 43.90%. Novo Nordisk A/S ability to meet debt levels, with a current ratio of 1.1, while the quick ratio is 0.8.
For the last year Novo Nordisk A/S, NVO has seen a EPS growth of 10.60%. A performance for the year of -16.21%. The 52-week high is -24.75%, and the 52-week low is 39.85%. The average volume for Novo Nordisk A/S, NVO is 2753595.
With a target price of 36.7, can Novo Nordisk A/S, NVO reach this target? Looking at the value indicators of Novo Nordisk A/S, NVO. Novo Nordisk A/S has a P/E of 18.82 and a forward P/E of 17.27. Perhaps the more useful indicator than P/E, is PEG which has a value of 1.98. Novo Nordisk A/S also has a P/S and a P/B of 4.98 and 17.85 respectively. For P/cash, Novo Nordisk A/S has a value of 31.71, while it is 22.49 for P/free cash flow.
At the current price of 43.2, Novo Nordisk A/S has a dividend yield of 2.59%. We see a return on equity of 91.20%.
Looking more long-term Novo Nordisk A/S, is projected to get an EPS growth for the next five years of 9.50%. In the short-term an EPS growth of 10.66% in the next year is forecasted. This is after a EPS growth of 10.60% for this year and for the last five years a 20.10% growth has been seen.